• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza Other Respir Viruses . Effectiveness of Influenza Vaccines in Italy in the 2024/2025 Season: A Nationwide, Test-Negative Design Study Base

tetano

Editor, Senior Moderator
Influenza Other Respir Viruses


. 2026 May;20(5):e70252.
doi: 10.1111/irv.70252.
Effectiveness of Influenza Vaccines in Italy in the 2024/2025 Season: A Nationwide, Test-Negative Design Study Based on Surveillance Records

Daniel Cifo[SUP] 1 2 [/SUP], Alberto Mateo-Urdiales[SUP] 3 [/SUP], Simona Puzelli[SUP] 3 [/SUP], Marzia Facchini[SUP] 3 [/SUP], Sara Piacentini[SUP] 3 [/SUP], Emanuela Giombini[SUP] 3 [/SUP], Benedetta Bellini[SUP] 3 [/SUP], Massimo Fabiani[SUP] 3 [/SUP], Patrizio Pezzotti[SUP] 3 [/SUP], Paola Stefanelli[SUP] 3 [/SUP], Anna Teresa Palamara[SUP] 3 [/SUP], Antonino Bella[SUP] 3 [/SUP]; RespiVirNet network


Affiliations
Abstract

The 2024/2025 influenza season in Italy was characterised by cocirculation of influenza A and B viruses. Monitoring influenza vaccine effectiveness (IVE) remains essential to guide public health policy due to antigenic shifts and varying strain circulation. In this study, we aimed to estimate IVE in primary care and hospital settings during the 2024/2025 season in Italy. A nationwide test-negative control design was used. Data were collected from the RespiVirNet surveillance system, encompassing both primary care and hospital settings. A total of 8842 participants were included in the primary care analysis and 2492 in the hospital analysis. Adjusted vaccine effectiveness (aVE) against any influenza virus was 69.0% (95% CI: 60.4%-75.9%) in primary care and 62.3% (95% CI: 45.9%-74.2%) in hospital settings. Effectiveness was highest among individuals under 18 years and decreased with age. Influenza B showed the highest aVE (83.6% in primary care; 95.0% in hospital settings), particularly among younger individuals. aVE for influenza A subtypes was lower, with A H1N1pdm09 (54.0% in primary care; 63.8% in hospital) and A H3N2 (60.1% in primary care; 45.5% in hospital) showing moderate effectiveness. The results suggest that influenza vaccines were effective in preventing medically attended influenza disease, both in primary care and hospital settings. These findings provide valuable insights for public health planning and vaccine policy in Italy.

Keywords: epidemiology; influenza; surveillance; vaccine effectiveness.

 
Back
Top Bottom